Zacks Research Brokers Lower Earnings Estimates for Theravance Biopharma, Inc. (NASDAQ:TBPH)

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Equities research analysts at Zacks Research dropped their Q3 2024 earnings per share estimates for shares of Theravance Biopharma in a research note issued on Monday, August 26th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will earn ($0.23) per share for the quarter, down from their previous forecast of ($0.18). The consensus estimate for Theravance Biopharma’s current full-year earnings is ($0.97) per share. Zacks Research also issued estimates for Theravance Biopharma’s Q4 2024 earnings at ($0.16) EPS, FY2024 earnings at ($0.97) EPS, Q3 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.21) EPS, Q1 2026 earnings at ($0.09) EPS, Q2 2026 earnings at ($0.07) EPS and FY2026 earnings at $0.49 EPS.

Several other equities analysts have also recently weighed in on TBPH. StockNews.com cut Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, August 10th. Leerink Partnrs lowered Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 6th. TD Cowen reduced their price objective on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating for the company in a research note on Tuesday, August 6th. Leerink Partners lowered Theravance Biopharma from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $15.00 to $10.00 in a research note on Tuesday, August 6th. Finally, HC Wainwright reduced their price objective on Theravance Biopharma from $20.00 to $15.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Theravance Biopharma presently has an average rating of “Hold” and an average price target of $13.75.

Theravance Biopharma Price Performance

NASDAQ TBPH opened at $8.38 on Wednesday. The business’s fifty day moving average price is $8.90 and its 200-day moving average price is $8.96. The stock has a market capitalization of $409.95 million, a price-to-earnings ratio of -9.74 and a beta of 0.24. Theravance Biopharma has a 1-year low of $7.44 and a 1-year high of $11.71.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.25). The business had revenue of $14.26 million during the quarter, compared to the consensus estimate of $15.81 million. Theravance Biopharma had a negative net margin of 73.61% and a negative return on equity of 21.29%. During the same period last year, the company posted ($0.28) earnings per share.

Institutional Trading of Theravance Biopharma

Institutional investors and hedge funds have recently modified their holdings of the stock. Gerber LLC bought a new stake in shares of Theravance Biopharma during the fourth quarter valued at approximately $112,000. Wellington Management Group LLP raised its stake in shares of Theravance Biopharma by 68.0% during the fourth quarter. Wellington Management Group LLP now owns 287,102 shares of the biopharmaceutical company’s stock valued at $3,227,000 after acquiring an additional 116,164 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Theravance Biopharma by 16.6% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 52,876 shares of the biopharmaceutical company’s stock valued at $474,000 after acquiring an additional 7,509 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Theravance Biopharma by 31.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,330 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 2,227 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Theravance Biopharma by 7.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 49,475 shares of the biopharmaceutical company’s stock valued at $444,000 after acquiring an additional 3,532 shares in the last quarter. Institutional investors own 99.10% of the company’s stock.

Insiders Place Their Bets

In other Theravance Biopharma news, major shareholder Eli Samaha purchased 999,800 shares of the business’s stock in a transaction on Wednesday, August 7th. The stock was acquired at an average price of $7.80 per share, for a total transaction of $7,798,440.00. Following the purchase, the insider now owns 9,511,150 shares of the company’s stock, valued at approximately $74,186,970. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, major shareholder Eli Samaha acquired 999,800 shares of the firm’s stock in a transaction on Wednesday, August 7th. The stock was acquired at an average price of $7.80 per share, with a total value of $7,798,440.00. Following the completion of the purchase, the insider now directly owns 9,511,150 shares in the company, valued at $74,186,970. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Rhonda Farnum sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 335,965 shares of the company’s stock, valued at approximately $3,023,685. The disclosure for this sale can be found here. 6.90% of the stock is currently owned by company insiders.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.